Calibrated screen addition guidance

Media & Entertainment → Result Update → May 16, 2023

PVR Inox's Q4FY23 results (first as a merged entity) reflected weak box office performance, as revenue declined by 21.5% QoQ to Rs11.4bn (pro-forma for Q3FY23), slightly below our estimates. Footfalls at 30.5mn were tad below our estimates, while ATP and SPH were broadly in-line. Bollywood's inconsistent performance persisted with only two movies breaching the Rs1bn barrier. The company has highlighted that it will shut 50 screens over the next six months, culling out non-profitable screens. Screen addition guidance of 150-175 screens for FY24 is slightly lower than the previously stated number of 180-200. Additionally, the company will realign the upcoming handover of new sites for fit outs till the full business recovers, indicating a calibrated strategy for screen additions. We have cut our FY24/25 EBITDA estimates by 10-15% to factor in screen closures, lower screen additions, and slower ramp-up in film releases and have arrived at a revised TP of Rs1,700, (11.5x Mar-25E pre IND-AS EBITDA)

PVR INOX: Financial Snapshot (Consolidated)									
Y/E March (Rs mn)	FY21	FY22	FY23	FY24E	FY25E				
Revenue	2,800	13,310	37,507	66,887	76,168				
EBITDA	(3,349)	1,057	10,473	22,642	26,677				
Adj. PAT	(7,472)	(4,882)	(3,273)	4,225	5,901				
Adj. EPS (Rs)	(123.0)	(80.4)	(52.0)	43.1	60.2				
EBITDA margin (%)	(119.6)	7.9	27.9	33.9	35.0				
EBITDA growth (%)	(131.1)	0.0	890.4	116.2	17.8				
Adj. EPS growth (%)	(2,811.1)	0.0	0.0	0.0	39.7				
RoE (%)	(45.1)	(30.5)	(7.5)	5.6	7.3				
RoIC (%)	(12.8)	(6.7)	5.0	6.7	7.6				
P/E (x)	NA	NA	NA	33.3	23.8				
EV/EBITDA (x)	NA	126.1	16.3	9.5	8.0				
P/B (x)	4.8	6.4	1.3	1.8	1.7				
FCFF yield (%)	(4.1)	0.3	1.3	5.5	3.9				

Source: Company, Emkay Research

Results Summary: PVR Inox's revenue fell by 21.5% QoQ/grew 33% YoY (pro-forma numbers) to Rs11.4bn in Q4FY23. ATP and SPH stood at Rs239 and Rs119, respectively, broadly in-line with our estimates, while footfalls of 30.5mn were marginally below our estimates. Footfalls in FY23 remained 16% lower than FY20 levels, indicating sluggish box office recovery, despite 14% growth in the number of screens. Reported EBITDA stood at Rs2.6bn, while adjusted for IND-AS, EBITDA stood at Rs54mn, below our estimate of Rs350mn. Weak EBITDA was on account of higher-than-estimated employee expenses. There were exceptional items of Rs1.6bn related to (1) Impairment of capital work in progress (Rs108.2mn); (2) Accelerated depreciation on cinemas proposed to be shut down (Rs105.8mn); (3) Merger-related expenses (Rs54.9mn); and (4) Deferred tax assets write-off (Rs1,343mn). PVR Inox reported net loss of Rs3.3bn in FY23. Net debt jumped to Rs14.3bn in FY23 from Rs9.2bn in FY22. The merged entity added 79 screens during O4FY23, taking the total additions to 168 for FY23. PVR Inox has guided for 150-175 screen additions for FY24, lower than its previous number of 180-200 screens.

Earnings Call KTAs: (1) Screen Opening: Mgmt. expects to open 150-175 screens in FY24 (gross addition). It expects box office volatility to stabilize before taking handover, hence it is realigning the upcoming handovers. PVR Inox will be closing 50 screens (in Tier-1 and Tier-2 cities) in the next six months. EBITDA boost of closing down these screens would be Rs100mn. Mgmt. is focusing on profitable growth and unit level economics. 40-50% of screens will be added in the South going ahead. Total capex should be Rs7bn for this year. (2) Ad revenue: The immediate aim is to get closer to pre-Covid levels. Mgmt. hopes to get stronger numbers by the start of the festive season. The merger has aided in driving synergies; and limiting under-cutting of prices. Mgmt. expects growth in both value and volume of ads. Currently, it is focused on getting volumes back. (3) Debt: Incremental debt has gone up to fund capex. Net debt in FY24 should be lower than FY23. New screens in FY24 will be funded via internal accruals. (4) Margins: Post-Covid, margins have fallen due to the negative impact of operating leverage. Mgmt. aims to get back to pre-Covid levels of 18-20% next year. (5) Quarter update and outlook: Q4 started off on a high note; February and March footfalls were dismal. Hollywood delivered a decent Q4 performance, while regional movies continued to perform strongly. Mgmt. expects volatility in box office collections to settle down in FY24. It expects Rs60-70bn revenue in FY24; these estimates are based on a strong movie line-up and screen opening. (6) Merger: Bulk of synergies are going to be on the revenue side. PVR Inox should see breakeven at the EBITDA level at occupancies of ~20% at normalized advertising levels.

TARGET PRICE (Rs): 1,700

Target Price – 12M	Mar-24
Change in TP (%)	(17.1)
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	18.4
CMP (16-May-23) (Rs)	1,435.2

Stock Data	Ticker
52-week High (Rs)	2,215
52-week Low (Rs)	1,403
Shares outstanding (mn)	98.0
Market-cap (Rs bn)	141
Market-cap (USD mn)	1,710
Net-debt, FY24E (Rs mn)	73,476
ADTV-3M (mn shares)	1
ADTV-3M (Rs mn)	818.5
ADTV-3M (USD mn)	10.0
Free float (%)	72.5
Nifty-50	18,287
INR/USD	82.2
Shareholding, Dec-20	
Promoters (%)	27.5
FPIs/MFs (%)	29.7/24.6

Price Performance								
(%)	1M	3M	12M					
Absolute	(6.2)	(16.1)	(17.6)					
Rel. to Nifty	(8.6)	(17.3)	(28.6)					

1-Year share price trend (Rs)



Pulkit Chawla pulkit.chawla@emkayglobal.com +91 22 6624 2458

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>Please refer to The last page of the report on restrictions on Distribution. In Singapore, this research report of research 5/ analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act. Chapter 289 of Singapore.

Exhibit 1: Actual vs. Estimates (Q4FY23)

(Rs mn) Actu		Actual		Variation		Comment	
(KS IIIII)	Actual	Emkay	Consensus	Emkay	Consensus		
Revenue	11,432	11,768	10,904	-3%	5%	Marginally lower footfalls	
EBITDA	2,639	2,979	2,624	-11%	1%	Higher employee expenses	
EBITDA, margin	23.1%	25.3%	24.1%	-223 bps	-98 bps		
PAT	-3,334	-761	-817	NA	NA		

Source: Company, Emkay Research

Exhibit 2: Quarterly financial snapshot

(Rs mn)	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	YoY (%)	QoQ (%)	FY23	FY22	YoY (%)
Net Sales	5,371	9,814	6,867	9,407	11,432	113	22	37,507	13,310	182
Total Sales	5,371	9,814	6,867	9,407	11,432	113	22	37,507	13,310	182
Film exhibition cost	1322	2389	1462	1677	2597	96	55	8,188	2,860	186
As a % of sales	24.6	24.3	21.3	17.8	22.7			21.8	21.5	
Cost of Materials	448	765	629	778	930	108	20	3,102	1,115	178
As a % of sales	8.3	7.8	9.2	8.3	8.1			8.3	8.4	
Employee costs	814	1040	947	943	1514	86	61	4,389	2,693	63
As a % of sales	15.2	10.6	13.8	10.0	13.2			11.7	20.2	
Repairs & maintenance	1788	2204	2292	3122	3752	110	20	11,355	5,585	103
As a % of sales	33.3	22.5	33.4	33.2	32.8			30.3	42.0	
Total Expenditure	4,373	6,398	5,331	6,519	8,793	101	35	27,041	12,253	121
EBITDA	999	3,416	1,537	2,888	2,639	164	-9	10,465	1,057	890
Depreciation	1,687	1,494	1,525	1,552	2,962	76	91	7,533	6,144	23
EBIT	(688)	1,922	11	1,335	(323)	-53	-124	2,932	(5,087)	-158
Other Income	425	209	164	201	218	-49	8	791	3,261	-76
Interest	1,252	1,280	1,277	1,275	1,886	51	48	5,716	4,982	15
Exceptional item	-	-	-	-	(108)			-108	0	
PBT	(1,515)	851	(1,102)	262	(2,100)	39	-903	(2,101)	(6,807)	-69
Tax	(460)	319	(387)	102	1,240	-369	1,112	1,274	-1,922	-166
PAT before MI	(1,055)	532	(715)	159	(3,340)	217	-2,198	(3,376)	(4,885)	-31
Minority interest	-	(2)	(3)	(2)	(6)	NA	170	-13	-2	-
PAT	(1,055)	534	(712)	162	(3,334)	216	-2,164	(3,362)	(4,883)	-31
Margins (%)						(bps)	(bps)			(bps)
EBIDTA	18.6	34.8	22.4	30.7	23.1	449	-762	27.9	7.9	1,996
EBIT	-12.8	19.6	0.2	14.2	-2.8	998	-1,702	7.8	-38.2	4,603
PBT	-28.2	8.7	-16.0	2.8	-18.4	984	-2,115	-5.6	-51.1	4,554
PAT	-19.6	5.4	-10.4	1.7	-29.2	-952	-3,088	-9.0	-36.7	2,772
Effective Tax rate	30.4	37.5	35.1	39.1	-59.0	-8,941	-9,816	-60.6	28.2	-8,887

Source: Company, Emkay Research. Financials are not comparable due to the merger in Q4FY23.

Exhibit 3: Change in Estimates

		FY24E		FY25E			
Particulars	Old	New	Change (%)	Old	New	Change (%)	
Revenue	72,859	66,887	-8.2	81,183	76,168	-6.2	
EBITDA	26,585	22,642	-14.8	29,662	26,677	-10.1	
EBITDA Margin (%)	36.5	33.9	-264 bps	36.5	35.0	-151 bps	
EBITDA (Adj. for IND AS)	15,473	11,992	-22.5	17,640	15,388	-12.8	
PAT	6,115	4,225	-30.9	7,951	5,901	-25.8	
EPS (Rs)	62.4	43.1	-30.9	81.2	60.2	-25.8	

Source: Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/17/2023 02:52 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 4: Box office recovery has been weak - FY23 footfalls lower despite a higher number of screens

Destination (IND Ma)	FY'23		FY'20			Classes
Particulars (INR Mn)	PVR + INOX	PVR	INOX	Total		Change
Screens*	1,680	845	626	1,471		14%
Admits (Mn)	140	102	66	168		-16%
Occupancy %	25.2%	34.9%	28.0%	31.8%		-21%
Gross ATP (INR)	236	204	200	203	16%	(CAGR: 5.2%)
Gross SPH (INR)	120	99	80	92	30%	(CAGR: 9.3%)
Financial Performance						
Sale of Movie Tickets	27,514	17,312	11,046	28,357		-3%
Sale of Food & Beverages	16,180	9,605	4,972	14,577		11%
Advertisement Income	3,818	3,759	1,790	5,549		-31%
Convenience Fees	2,470	1,719	668	2,387		3%
Other Income	3,124	2,128	670	2,798		12%
Total Income	53,105	34,522	19,146	53,668		-1%
Total Expenses	47,012	28,383	15,678	44,061		7 %
EBITDA	6,093 (1)	6,139	3,468	9,607		-37 %
EBITDA Margin	11.5%	17.8%	18.1%	17.9%		-6 %

Source: Company

Exhibit 5: Operational parameters comparison

Q4, FY'23 vs Q4, FY'22;

2-,,						
Particulars	Q4, FY'23	Q	4, FY'22	% Change	12M, FY'23	12M, FY'22
Operating Numbers	PVR INOX Reported (A)	PVR Reported	PVR + INOX Proforma (B)	(A/B) -1	PVR INOX Reported	PVR Reported
Cinemas	359	181	341	5%	359	181
Screens*	1,680	871	1,546	9%	1,680	871
Seats	357k	184k	336k	6%	357k	184k
Admits (Mns)	30.5	14.3	25.3	20%	95.1	33.5
Occupancy (%)	22.2%	26.0%	25.1%	-290 bps	26.4%	22.1%
ATP (INR)	239	242	232	3%	240	235
SPH (INR)	119	122	106	13%	128	124

12M, FY'23 vs 12M, FY'22

Source: Company

PVR INOX: Consolidated Financials and Valuations

Profit and Loss					
Y/E March (Rs mn)	FY21	FY22	FY23	FY24E	FY25E
Revenue	2,800	13,310	37,507	66,887	76,168
Revenue growth (%)	(91.8)	375.3	181.8	78.3	13.9
EBITDA	(3,349)	1,057	10,473	22,642	26,677
EBITDA growth (%)	(131.1)	0.0	890.4	116.2	17.8
Depreciation & Amortization	5,749	6,144	7,533	10,000	12,000
EBIT	(9,097)	(5,087)	2,940	12,642	14,677
EBIT growth (%)	(270.3)	0.0	0.0	330.0	16.1
Other operating income	0	0	0	0	0
Other income	4,693	3,261	791	1,280	1,400
Financial expense	4,978	4,982	5,716	8,277	8,191
PBT	(9,382)	(6,807)	(1,986)	5,646	7,887
Extraordinary items	0	0	(108)	0	0
Taxes	(1,906)	(1,922)	1,274	1,421	1,985
Minority interest	(4)	(3)	13	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	(7,472)	(4,882)	(3,381)	4,225	5,901
PAT growth (%)	(2,811.1)	0.0	0.0	0.0	39.7
Adjusted PAT	(7,472)	(4,882)	(3,273)	4,225	5,901
Diluted EPS (Rs)	(123.0)	(80.4)	(52.0)	43.1	60.2
Diluted EPS growth (%)	(2,811.1)	0.0	0.0	0.0	39.7
DPS (Rs)	0.0	0.0	0.0	0.0	0.0
Dividend payout (%)	0.0	0.0	0.0	0.0	0.0
EBITDA margin (%)	(119.6)	7.9	27.9	33.9	35.0
EBIT margin (%)	(324.9)	(38.2)	7.8	18.9	19.3
Effective tax rate (%)	20.3	28.2	(64.2)	25.2	25.2
NOPLAT	(7,249)	(3,650)	4,826	9,460	10,983
Shares outstanding (mn)	60.8	60.8	65.0	98.0	98.0

Source: Company, Er	nkay Research
---------------------	---------------

Cash flows					
Y/E March (Rs mn)	FY21	FY22	FY23	FY24E	FY25E
PBT	(9,382)	(6,807)	(1,986)	5,646	7,887
Others (non-cash items)	5,993	7,943	12,589	8,277	8,191
Taxes paid	72	99	1	(1,421)	(1,985)
Change in NWC	(803)	434	(1,969)	4,746	(2,398)
Operating cash flow	(4,121)	1,668	8,635	17,247	11,694
Capital expenditure	(1,166)	(1,298)	(6,339)	(5,543)	(3,361)
Acquisition of business	0	0	0	0	0
Interest & dividend income	28	270	88	0	0
Investing cash flow	(2,886)	(28)	(5,759)	(5,543)	(3,361)
Equity raised/(repaid)	10,931	183	305	0	0
Debt raised/(repaid)	1,768	1,533	1,260	(3,000)	(1,000)
Payment of lease liabilities	(962)	(2,638)	(7,059)	626	632
Interest paid	(982)	(1,246)	(1,442)	(8,277)	(8,191)
Dividend paid (incl tax)	0	0	0	0	0
Others	0	0	0	0	0
Financing cash flow	10,755	(2,168)	(6,935)	(10,651)	(8,559)
Net chg in Cash	3,748	(528)	(4,059)	1,053	(225)
OCF	(4,121)	1,668	8,635	17,247	11,694
Adj. OCF (w/o NWC chg.)	(4,924)	2,102	6,666	21,992	9,296
FCFF	(5,287)	370	2,296	11,703	8,333
FCFE	(10,238)	(4,342)	(3,333)	3,427	143
OCF/EBITDA (%)	123.1	157.7	82.5	76.2	43.8
FCFE/PAT (%)	137.0	88.9	98.6	81.1	2.4
FCFF/NOPLAT (%)	72.9	(10.1)	47.6	123.7	75.9

Source: Company, Emkay Research

Balance Sheet					
Y/E March (Rs mn)	FY21	FY22	FY23	FY24E	FY25E
Share capital	608	610	980	980	980
Reserves & Surplus	17,728	13,093	72,319	76,543	82,445
Net worth	18,335	13,703	73,299	77,523	83,425
Minority interests	0	(3)	(7)	(7)	(7)
Deferred tax liability (net)	(3,987)	(5,925)	(4,735)	(4,735)	(4,735)
Total debt	50,031	51,959	80,519	78,145	77,777
Total liabilities & equity	64,380	59,734	149,076	150,926	156,460
Net tangible fixed assets	14,904	15,181	29,431	34,431	37,431
Net intangible assets	1,773	1,590	1,480	1,776	1,865
Net ROU assets	27,554	26,784	53,746	53,746	53,746
Capital WIP	2,172	645	2,473	2,721	2,993
Goodwill	10,520	10,520	57,428	57,428	57,428
Investments	12	5	2,312	2,312	2,312
Cash & equivalents	7,311	5,798	3,616	4,669	4,443
Current assets (ex-cash)	6,786	6,788	9,510	17,006	16,900
Current Liab. & Prov.	6,654	7,573	10,922	23,163	20,659
NWC (ex-cash)	132	(785)	(1,411)	(6,157)	(3,759)
Total assets	64,380	59,738	149,076	150,926	156,460
Net debt	42,719	46,161	76,903	73,476	73,334
Capital employed	64,380	59,734	149,076	150,926	156,460
Invested capital	54,885	53,290	140,674	141,225	146,711
BVPS (Rs)	301.8	225.5	1,127.2	791.3	851.5
Net Debt/Equity (x)	2.3	3.4	1.0	0.9	0.9
Net Debt/EBITDA (x)	(12.8)	43.7	7.3	3.2	2.7
Interest coverage (x)	(1.1)	(2.7)	1.5	0.6	0.5
RoCE (%)	(6.9)	(2.9)	3.6	9.3	10.5

Source: Company, Emkay Research

Valuations and Key Ratios					
Y/E March	FY21	FY22	FY23	FY24E	FY25E
P/E (x)	NA	NA	NA	33.3	23.8
P/CE(x)	NA	69.1	21.9	9.9	7.9
P/B (x)	4.8	6.4	1.3	1.8	1.7
EV/Sales (x)	46.4	10.0	4.5	3.2	2.8
EV/EBITDA (x)	NA	126.1	16.3	9.5	8.0
EV/EBIT(x)	NA	NA	57.9	16.9	14.6
EV/IC (x)	2.4	2.5	1.2	1.5	1.5
FCFF yield (%)	(4.1)	0.3	1.3	5.5	3.9
FCFE yield (%)	(11.7)	(5.0)	(3.6)	2.4	0.1
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0
DuPont-RoE split					
Net profit margin (%)	(266.8)	(36.7)	(8.7)	6.3	7.7
Total asset turnover (x)	0.0	0.2	0.4	0.4	0.5
Assets/Equity (x)	3.9	3.9	2.4	2.0	1.9
RoE (%)	(45.1)	(30.5)	(7.5)	5.6	7.3
DuPont-RoIC					
NOPLAT margin (%)	(258.9)	(27.4)	12.9	14.1	14.4
IC turnover (x)	0.0	0.2	0.4	0.5	0.5
RoIC (%)	(12.8)	(6.7)	5.0	6.7	7.6
Operating metrics					
Core NWC days	17.3	(21.5)	(13.7)	(33.6)	(18.0)
Total NWC days	17.3	(21.5)	(13.7)	(33.6)	(18.0)
Fixed asset turnover	0.0	0.2	0.3	0.4	0.4
Opex-to-revenue (%)	202.7	70.6	50.2	43.2	42.1

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
19-Jan-23	1,678	2,050	Buy	Pulkit Chawla

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Bloomberg, Company, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India, EGFSL was established in 1995 and is one of India's leading brokerage and distribution house, EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkavglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness quaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests 2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

1 An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of May 16, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report 3. during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of May 16, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject 5 company at the end of the month immediately preceding the May 16, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company,

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.